Amgen Seeks Injunction To Block Hospira's Epoetin Alfa Biosimilar

Just one day after an FDA advisory panel urged approval of Hospira's epoetin alfa biosimilar, innovator Amgen took to the courts in an attempt to block the biosimilar from coming to market until Hospira has complied with the biosimilar pathway's notice of commercial marketing provisions. The move comes as the U.S. Supreme Court mulls how to interpret the Biologics Price Competition and Innovation Act's notice of commercial marketing provisions. “Plaintiffs Amgen Inc. and Amgen Manufacturing, Limited (together, 'Amgen') move for...